Abby A. Li has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Investigation of Ethylene Oxide Genotoxicity Dose–Response to Inform Cancer Risk Assessment

    by B. Bhaskar Gollapudi, James E. Bus, Phillip Cassidy, Jeffrey T. Weinberg, Jeffrey C. Bemis, Dorothea K. Torous, Stephen D. Dertinger, Kun Lu, Richard Reiss, Abby A. Li

    Ethylene oxide (EtO) is primarily used as an intermediate in the manufacture of chemicals, with a minor use as a sterilant for medical equipment and food products. It is a direct‐acting alkylating agent that reacts with cellular macromolecules, including proteins and DNA. EtO has been shown to induce tumors in rodents and humans. DNA reactivity has been the postulated mode of action (MOA) for its carcinogenicity. The current study has investigated the dose response for EtO‐induced genetic damage to inform the biological plausibility of a dose–response model for cancer risk assessment. Male and female B6C3F1 mice (≥ 10/sex/concentration) were exposed to 0, 0.05, 0.1, 0.5, 1, 50, 100, or 200 ppm EtO by whole‐body inhalation (6 h/day for 28 days, 7 days/week). Mutagenicity was assessed by determining the frequency of mutant Pig‐a phenotype in reticulocytes (RET) and mature red blood cells (RBC) on Day 28. Cytogenetic damage was evaluated by the erythrocyte micronucleus (MN) test in blood samples collected on Days 5 and 28. EtO is a relatively weak genotoxicant with treatment‐related increases in Pig‐a and MN frequencies being seen primarily at 200 ppm. The hockey‐stick shaped dose response for genetic damage may be conservatively interpreted as being no more than a linear response with a single slope. Thus, a cancer risk assessment dose–response model consisting of a single shallow linear slope throughout the exposure range is biologically plausible and consistent if EtO were acting through a mutagenic MoA for its carcinogenicity.

  • Open Access

    INVESTIGATION OF ETHYLENE OXIDE GENOTOXICITY DOSE-RESPONSE TO INFORM CANCER RISK ASSESSMENT

    by B. Bhaskar Gollapudi, James E. Bus, Phillip Cassidy, Jeffrey T. Weinberg, Jeffrey C. Bemis, Dorothea. K. Torous, Stephen D. Dertinger, Kun Lu, Abby A. Li

    Ethylene oxide (EtO) is primarily used as an intermediate in the manufacture of chemicals, with a minor use as a sterilant for medical equipment and food products. It is a direct-acting alkylating agent that reacts with cellular macromolecules, including proteins and DNA. EtO has been shown to induce tumors in rodents and humans. DNA reactivity has been the postulated mode of action (MOA) for its carcinogenicity. The current study has investigated the dose response for EtO-induced genetic damage to inform the biological plausibility of a dose-response model for cancer risk assessment. Male and female B6C3F1 mice were exposed to 0, 0.05, 0.1, 0.5, 1, 50, 100, or 200 ppm EtO by whole-body inhalation (6 hours/day for 28 days, 7 days/week). Mutagenicity was assessed by determining the frequency of mutant Pig-a phenotype in reticulocytes (RET) and mature red blood cells (RBC) on Day 28. Cytogenetic damage was evaluated by the erythrocyte micronucleus (MN) test in blood samples collected on Days 5 and 28. EtO is a relatively weak genotoxicant with treatment-related increases in Pig-a and MN frequencies being seen primarily at 200 ppm. The hockey-stick shaped dose response for genetic damage may be conservatively interpreted as being no more than a linear response with a single slope. Thus, a cancer risk assessment dose-response model consisting of a single linear slope throughout the exposure range is biologically plausible and consistent if EtO were acting through a mutagenic MoA for its carcinogenicity.

  • Open Access

    Characterization of Background Exposures to Ethylene Oxide in the United States: A Reality Check on Theoretical Health Risks for Potentially Exposed Populations near Industrial Sources

    by Christopher R. Kirman, Patrick J. Sheehan, Abby A. Li, James S. Bus, Steave H. Su, Pamela J. Dopart, Heather N. Watson, Emma E. Moynihan, Rick Reiss

    Ethylene oxide (EO) is an industrial chemical and sterilant that is released into ambient air from natural and unregulated anthropogenic sources that contribute to background exogenous exposure and from regulated industrial sources that contribute to additional exogenous exposure for near-facility populations. Metabolic processes contribute to substantial background endogenous exposures to EO, complicating the interpretation of the relation between total background exposure and the health significance of added industrial exogenous exposure. In 2021, Kirman and colleagues characterized the total and endogenous equivalent background concentrations for U.S. populations, which are substantially greater than the USEPA 2016 EO cancer reassessment risk-specific concentrations (0.00011–0.011 ppb), suggesting that the consideration of background exposure could be used as a reality check for the utility of the reassessment in managing EO risk for industrially exposed populations. New exposure biomarker data and background ambient concentration data for EO have become available since the 2021 assessment and are used here to refine the estimates of U.S. population total and endogenous equivalent background EO concentrations. Refined equivalent background concentrations as well as total equivalent exposure estimates for U.S. smokers provide context as to the health significance of near-industry population added exposure and a reality check for the utility of USEPA and TCEQ risk-specific concentrations in managing and communicating EO risk.


  • Open Access

    Genotoxicity as a toxicologically relevant endpoint to inform risk assessment: A case study with ethylene oxide

    by Bala Bhaskar Gollapudi, Steave Su, Abby A. Li, George E. Johnson, Richard Reiss, Richard J. Albertini

    The purpose of the present investigation is to analyze the in vivo genotoxicity dose–response data of ethylene oxide (EO) and the applicability of the derived point‐of‐departure (PoD) values when estimating permitted daily exposure (PDE) values. A total of 40 data sets were identified from the literature, and benchmark dose analyses were conducted using PROAST software to identify a PoD value. Studies employing the inhalation route of exposure and assessing gene or chromosomal mutations and chromosomal damage in various tissues were considered the most relevant for assessing risk from EO, since these effects are likely to contribute to adverse health consequences in exposed individuals. The PoD estimates were screened for precision and the values were divided by data‐derived adjustment factors. For gene mutations, the lowest PDE was 285 parts per trillion (ppt) based on the induction of lacI mutations in the testes of mice following 48 weeks of exposure to EO. The corresponding lowest PDE value for chromosomal mutations was 1,175 ppt for heritable translocations in mice following 8.5 weeks of EO exposure. The lowest PDE for chromosomal aberrations was 238 ppt in the mouse peripheral blood lymphocytes following 48 weeks of inhalation exposure. The diverse dose–response data for EO‐induced genotoxicity enabled the derivation of PoDs for various endpoints, tissues, and species and identified 238 ppt as the lowest PDE in this retrospective analysis.


  • Practical considerations for developmental thyroid toxicity assessments: What's working, what's not, and how can we do better?

    by Abby A. Li, Susan L. Makris, M. Sue Marty, Volker Strauss, Mary E. Gilbert, Ann Blacker, Leah M. Zorrilla, Pragati S. Coder, Bethany Hannas, Sheri Lordi, et al.


  • Open Access

    Reevaluation of Historical Exposures to Ethylene Oxide Among U.S. Sterilization Workers in the National Institute of Occupational Safety and Health (NIOSH) Study Cohort

    by Kenneth T. Bogen, Patrick J. Sheehan, Ciriaco Valdez-Flores, Abby A. Li

    The 2016 U.S. Environmental Protection Agency (EPA) Integrated Risk Information System (IRIS) assessment for ethylene oxide (EO) estimated a 10−6 increased inhalation cancer risk of 0.1 parts per trillion, based on National Institute of Occupational Safety and Health (NIOSH) epidemiology studies of sterilization facility workers exposed to EO between 1938 and 1986. The worker exposure estimates were based on a NIOSH statistical regression (NSR) model “validated” with EO levels measured after 1978. Between 1938 and 1978, when EO data was unavailable, the NSR model predicts exposures lowest in 1938 increasing to peak levels in 1978. That increasing EO concentration trend arose, in part, because engineering/industrial-hygiene (E/IH) factors associated with evolving EO-sterilization equipment and operations before 1978 were not properly considered in the NSR model. To test the NSR model trend prediction, a new E/IH-based model was developed using historical data on EO kill concentrations, EO residue levels in sterilized materials, post-wash EO concentrations in a sterilization chamber, and information on facility characteristics and sterilizer operator practices from operators familiar with pre-1978 industry conditions. The E/IH 90th percentile of 8 h time-weighted average EO exposures (C90) for highly exposed sterilizer operators was calibrated to match 1978 C90 values from the NSR model. E/IH model C90 exposures were estimated to decrease over time from levels 16 and were four-fold greater than NSR-estimated exposures for workers during 1938–1954 and 1955–1964. This E/IH modeled trend is opposite to that of NSR model predictions of exposures before 1978, suggesting that EPA’s exclusive reliance on the NIOSH cohort to estimate EO cancer risk should be re-examined.


  • Open Access

    Pesticide Exposure and Neurodevelopmental Outcomes: Review of the Epidemiologic and Animal Studies

    by Carol J. Burns, Laura J. McIntosh, Pamela J. Mink, Anne M. Jurek, Abby A. Li

    Assessment of whether pesticide exposure is associated with neurodevelopmental outcomes in children can best be addressed with a systematic review of both the human and animal peer-reviewed literature. This review analyzed epidemiologic studies testing the hypothesis that exposure to pesticides during pregnancy and/or early childhood is associated with neurodevelopmental outcomes in children. Studies that directly queried pesticide exposure (e.g., via questionnaire or interview) or measured pesticide or metabolite levels in biological specimens from study participants (e.g., blood, urine, etc.) or their immediate environment (e.g., personal air monitoring, home dust samples, etc.) were eligible for inclusion. Consistency, strength of association, and dose response were key elements of the framework utilized for evaluating epidemiologic studies. As a whole, the epidemiologic studies did not strongly implicate any particular pesticide as being causally related to adverse neurodevelopmental outcomes in infants and children. A few associations were unique for a health outcome and specific pesticide, and alternative hypotheses could not be ruled out. Our survey of the in vivo peer-reviewed published mammalian literature focused on effects of the specific active ingredient of pesticides on functional neurodevelopmental endpoints (i.e., behavior, neuropharmacology and neuropathology). In most cases, effects were noted at dose levels within the same order of magnitude or higher compared to the point of departure used for chronic risk assessments in the United States. Thus, although the published animal studies may have characterized potential neurodevelopmental outcomes using endpoints not required by guideline studies, the effects were generally observed at or above effect levels measured in repeated-dose toxicology studies submitted to the U.S. Environmental Protection Agency (EPA). Suggestions for improved exposure assessment in epidemiology studies and more effective and tiered approaches in animal testing are discussed.


  • Open Access

    Potential Effects of Chlorpyrifos on Fetal Growth Outcomes: Implications for Risk Assessment

    by Pamela J. Mink, Carole A. Kimmel, Abby A. Li

    Chlorpyrifos (CPF) is one of the most widely used organophosphate insecticides in the United States. By December 2000, nearly all residential uses were voluntarily canceled, so that today, CPF is only used to control insect pests on a variety of crops. Periodic review of the potential effects of CPF on all developmental outcomes is necessary in the United States because the Food Quality Protection Act mandates special consideration of risk assessments for infants and children. This article reviews epidemiologic studies examining the association of potential CPF exposure with growth indices, including birth weight, birth length, and head circumference, and animal studies focusing on related somatic developmental endpoints. It differs from earlier reviews by including an additional cohort study and providing in-depth systematic evaluation of the patterns of association across different studies with respect to specificity of biomarkers for CPF, consistency, dose response, strength of association, temporality, and biological plausibility (Hill 1965), as well as consideration of the potential role of effect modification and bias. The review did not identify any strong associations exhibiting consistent exposure-response patterns that were observed in more than one of the four cohort studies evaluated. In addition, the animal data indicate that developmental effects occur at doses that produce substantial maternal toxicity and red blood cell (RBC) acetylcholinesterase (AChE) inhibition. Based on consideration of both the epidemiologic and animal data, maternal RBC AChE inhibition is a more sensitive endpoint for risk assessment than somatic developmental effects reviewed in this article.


  • Integration of epidemiology and animal neurotoxicity data for risk assessment

    by Abby A. Li, Tina E. Levine, Carol J. Burns, W. Kent Anger